Background. Emerging data suggest a link between calpain activation and the enhanced inflammatory response of the cardiovascular system. We hypothesize that calpain activation associates with altered inflammatory protein expression in correlation with the proinflammatory profile of the myocardium. Our pig hypercholesterolemic model with chronic myocardial ischemia was treated with calpain inhibitors to establish their potential to improve cardiac function. Methods. Yorkshire swine, fed a high cholesterol diet for 4 weeks then underwent placement of an ameroid constrictor on the left circumflex artery. Two weeks later, animals received either no drug (high-cholesterol control group, n = 8), a low dose of calpain inhibitors (0.12 mg/kg, n = 9), or a high dose of calpain inhibitors (0.25 mg/kg; n = 8). The high-cholesterol diet and calpain inhibitors were continued for 5 weeks, after which the pig was euthanized. The left ventricular myocardial tissue (ischemic and nonischemic) was harvested and analyzed for inflammatory protein expression. Data were statistically analyzed via the Kruskal-Wallis and Dunn post hoc test. Results. Calpain inhibitor treatment coincides with increased expression of IKB-a and decreased expression of macrophages, NFkB, IL-1, and tumor necrosis factor (TNF)-a in the ischemic myocardial tissue as compared with the control group. An NFkB array revealed decreased expression of IRF5, JNK1/ 2, JNK2, CD18, NFkB p65, c-Rel, Sharpin, TNF R1, TNF R2, and DR5 in the ischemic myocardium of the group treated with a high dose of calpain inhibitors compared with the control. Conclusion. Calpain activation in metabolic syndrome is a potential contributor to cardiac dysfunction in metabolic disorders with ischemic background. We suggest that calpain inhibition downregulates NFkB signaling in the vessel walls, which might be useful for improving myocardial blood flow in ischemic conditions. (Surgery 2017;161:1394-404.) 
CVD and concurrent metabolic syndrome have an increased rate of total mortality compared with patients with CVD alone. 3 Some of the metabolic syndrome associated vascular endothelial dysfunction is likely attributed to an increased inflammatory response. Inflammatory stimuli could cause disruption of the endothelial barrier facilitating migration of leukocytes through the vessel wall thus causing vascular inflammation. This inflammation may lead to atherosclerotic disease. 4 Calpains are a class of calcium-dependent proteases with a wide range of targets, including members of the inflammatory cascade. 5 Calpain activity has been found to promote leukocyteendothelial rolling, change platelet function, proteolytically cleave proteins resulting in hyperaggregability, as well as modulate tumor necrosis factor-alpha (TNF-a) and other proinflammatory markers. [6] [7] [8] [9] [10] Recent studies have reported that calpain inhibition exerts anti-inflammatory effects on cardiac tissue leading to improved function. 11 We developed a large-animal model that represents the pathologic abnormalities seen in adult patients with coronary artery disease and metabolic syndrome. 12 Using this model, we have found that calpain inhibition improves myocardial blood flow and also promotes expression of proteins that are involved in angiogenesis. 13 To gain a better understanding of the mechanisms by which exposure to calpain inhibitors may improve myocardial blood flow, we have taken advantage of our chronic myocardial ischemia metabolic syndrome model. Results reported herein demonstrate that the calpain inhibition in our metabolic syndrome pig model alters the expression of inflammatory markers in the ischemic myocardial tissue. Consequently, therapies aimed at calpain inhibition in inflammatory ischemic metabolic syndrome states might be useful for preventing inflammation and improving cardiac function.
METHODS
Animal model. The animal model used in this study has been previously described. [13] [14] [15] Briefly, to induce metabolic syndrome, 25 Yorkshire Swine (E. M. Parsons and Sons, Hadley, MA) were fed a highfat/high-cholesterol diet (4% cholesterol, 2.3% corn oil, 17.2% coconut oil, 1.5% sodium cholate, and 75% regular chow) for 4 weeks (Sinclair Research, Columbia, MO). To induce chronic myocardial ischemia, the pigs then underwent a procedure to place an ameroid constrictor on their left circumflex artery to induce chronic coronary artery ischemia. 16 Two weeks later, animals received either no drug, (high-cholesterol control group, CON; n = 8), a low dose of the calpain inhibitor (CI), MDL28170, drug (0.12 mg/kg daily; LCI, n = 9), or a high dose of CI MDL28170 (CI; 0.25 mg/kg daily; HCI, n = 8). The high-cholesterol diet and CI were continued for 5 weeks. The pigs then underwent a harvest procedure and the endocardial tissue was collected from the chronically ischemic myocardium and the nonischemic myocardium.
The Rhode Island Hospital Institutional Animal Care and Use Committee approved and supervised all experiments. The Principles of Laboratory Animal Care formulated by the National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals were used to ensure proper care of all animals.
Protein expression. The Western blot analysis was performed as previously described.
14 Polyvinylidene difluoride membranes (Millipore, Billerica, MA) were primed with primary antibodies against p-IkB-a (ser32), nuclear factor kappa B (NFkB [p65]), interferon gamma (IFN-g), TNF-a, interleukin-1 (IL-1), intercellular adhesion molecule (CD54/ICAM-1), vascular cell adhesion molecule (VCAM), inducible nitric oxide synthase (iNOS), and protein kinase C alpha (PKC-a) (Cell Signaling, Danvers, MA).
ImageJ software (National Institute of Health, Bethesda, MD) was used to quantify immunologic reactions as arbitrary light units. Loading error was controlled for by probing membranes with an antibody against GAPDH. GraphPad 5.0 software (GraphPad Software Inc, San Diego, CA) was used to perform Kruskal-Wallis test with Dunn multiple comparisons between the 3 groups.
Immunohistochemistry. Immunohistochemistry was performed as previously described. 13 Briefly, frozen section slides of the individual groups were incubated with antibodies to smooth muscle a-actin, NFkB p65, IkBa (Cell Signaling, Danvers, MA) and macrophage (MAC397; Abcam, Cambridge, MA). Images for NFkB p65 and IkBa were captured at 40X magnification with a Nikon E800 Eclipse microscope (Nikon, Tokyo, Japan) at the same exposure in 5 random fields. ImageJ software was used to quantify mean intensity of respective antibodies. Representative images are included in the paper. Images for macrophage antibody (MAC397) were analyzed at 40X magnification with a Nikon E800 Eclipse microscope (Nikon). Macrophages were counted for each specimen (1 specimen per pig), and totals were divided by specimen area. Representative images are included in the article.
Proteome profiler. The NFkB Pathway Array Kit (ARY029; R&D Systems, Minneapolis, MN) was used to evaluate the expression of inflammatory markers between calpain treated and untreated metabolic syndrome pigs by following the protocol of the supplier. Total tissue lysate samples from CON and HCI pigs were pooled prior to placement on membranes. ImageJ software was used to Data analysis. Western blot data were normalized to GAPDH for each protein tested. Results are reported as fold change values compared with the high-cholesterol diet (CON) group +/À standard error of the mean (SEM). Immunohistochemistry for IkBa and NFkB are reported as average mean intensity (in pixels)/40XHPF +/À SEM. Five random fields were analyzed for each pig.
Immunohistochemistry for macrophages are reported as average macrophage count/area +/À SEM. Western blot and immunohistochemistry data were analyzed using Kruskal-Wallis analysis of variance (ANOVA) and Dunn post hoc comparisons. The NFkB protein array data are reported as average mean intensity. Data were analyzed by 2-tailed, unpaired t test; all data were analyzed using GraphPad Prism 5.0 Software (GraphPad Software Inc).
RESULTS
Ischemic myocardial tissue. Western blot. In the ischemic myocardial tissue, there was a strong trend toward decreased expression of NFk-B in both calpain-inhibited groups compared with the control group (P = .53). There was a decrease in expression of TNF-a in the LCI group compared with the control group and a decrease in Il-1 in the HCI group compared with the control group. There was an increase in ICAM in the LCI group compared with the control group and an increase in PKC-a in the HCI group compared with the control group. There was a trend toward decrease in IFN-g in the calpain-inhibited groups compared with the control (P = .13; Fig 1) . The expression of VCAM, p-IkB-a, and i-NOS showed no clear trends in the calpain-inhibited groups compared with the control (Table I) .
Immunohistochemistry. There was increased expression of IkBa in the HCI and LCI groups compared with the control group (Fig 2) . There was decreased expression of NFkB p65 in the HCI group compared with the control and a trend toward decreased expression in the LCI group compared with the control (Fig 3) . Interestingly, the expression of IkBa and NFkB p65 was localized to the vessel walls (which were costained with smooth muscle a actin [SMA]).
NFkB protein array. Protein array analysis showed that in the ischemic tissue there was decreased expression of interferon regulator factor 5 (IRF 5), c-Jun N-terminal kinase one-half (JNK 1/2), c-Jun N-terminal kinase 2 (JNK 2), NFkB p65, protooncogene c-Rel (c-REL), Shank-associated RH domain interacting ProtIN (sharpin), TNF-a receptor 1 (TNFR1), TNF-a receptor 2 (TNFR 2), and TNF-related apoptosis inducing ligand receptor 2 (TRAIL R2) in the HCI group compared with the control (Table I) .
Macrophage counts. In the ischemic tissue, there was increased expression of macrophage counts/ mm 2 in the control group compared with the HCI and LCI groups (Fig 4) .
Nonischemic myocardial tissue. In the nonischemic myocardial tissue, there was decreased expression of VCAM in both the HCI and LCI groups and a significant decrease in the expression of ICAM in the LCI group compared with the HCI group. However, there was no significant difference in ICAM between either calpain-inhibited group and the control (Fig 5) . Calpain inhibition had no significant effect on the expression of Il-1, ICAM, PKC-a, IFN-g, IL-1, p-IKB alpha, or NFkB in the nonischemic myocardial tissue (Table II) .
DISCUSSION
To date, most studies directed at understanding the mechanisms that underlie the inflammatory shift during cardiac ischemia and metabolic syndrome have been performed with murine models. In the present study, we have taken advantage of the pig metabolic syndrome model and proteomics analyses to examine the inflammatory disturbances that may arise from inflammatory processes in the heart and the potential of calpain inhibitors to reverse inflammation.
We hypothesized that calpain inhibition would beneficially alter inflammatory protein expression in the ischemic myocardial tissue in our pig model of diet-induced metabolic syndrome. We found that in the setting of metabolic syndrome and chronic myocardial ischemia, inhibition of calpain has a beneficial effect on vessel wall NFkB inflammatory signaling and is associated with decreased macrophage presence in ischemic myocardial tissue. Importantly, our results suggest that calpain inhibition functions by stabilizing the expression of IkBa, allowing IkBa to bind to NFkB sequestering it in the cytosol. Our results were corroborated using Western blot, immunohistochemistry, and protein array showing that NFkB signaling is modified by calpain inhibition. This suggests that the beneficial effect seen by calpain inhibition on myocardial blood flow may be through its inhibitory effect on the inflammatory cascade.
IkBa inhibits the transcription factor activity of NFkB by binding to it and sequestering it in the cytoplasm. IkBa is inactivated by stimuli associated with stress, such as ischemia. This inactivation occurs via phosphorylation by IKK at serine-32 and serine-36, tagging the protein for degradation. IKK is a multicomponent protein complex comprised of IKKa/a, IKKb/2 and IKKg. 17, 18 Inactivation and degradation of IkBa thus frees NFkB allowing it to translocate to the nucleus where it promotes transcription of a number of inflammatory genes, including cytokines, chemokines, and adhesion molecules. 19 Calpain activation is thought to degrade IkBa via direct cleavage. Interestingly, calpain has been found to cleave between amino acid 50 and 51. Cleavage at this site results in a liberated fragment that contains the serine and threonine residues necessary for phosphorylation by the IKK complex. In situations of stress, inhibition of calpain is associated with increased levels of IkBa. 20 Our Western blot analysis showed a strong trend to decrease in NFkB and no difference in p-IkBa in calpain-inhibited groups compared with the control. It is possible that we did not see a significant difference in NFkB because the Western blot was showing us difference in total myocardial tissue lysate without tissue-specific localization. It is likely that we did not see a difference in p-IkBa because calpain regulates IkBa in a manner that does not involve phosphorylation.
Therefore, to clarify this issue, we performed additional immunohistochemistry; in doing so, we were able to not only quantify the changes in expression of proteins between groups, but also localize the proteins in the myocardial tissue. Our immunohistochemistry analysis shows that calpain inhibition is associated with increased expression of the active form of IkBa and decreased expression of the active form of NFkB (p65). Importantly, we also found that the changes in expression of IkBa and NFkB were seen in the vascular smooth muscle cells (as identified by costaining with SMA). This suggests a mechanism through which calpain inhibition may have a beneficial effect on myocardial blood flow via an inhibitory effect on the inflammatory cascade.
Importantly, our Western blot analysis shows that calpain inhibition decreases the expression of downstream targets of the transcription factor of NFkB, including the strong proinflammatory cytokines TNF-a, IL-1, and IFN-g. This is consistent with previous research, which shows that sepsis-induced calpain activation leads to increased expression of TNF-a in cardiomyocytes and that calpain inhibition improves myocardial function in endotoxemia. 11 In the ischemic myocardial tissue, we did not see any significant trends in VCAM or iNOS in the calpain-inhibited groups compared with the control. It is possible that we did not see a significant difference because the Western blot was showing us difference in total myocardial tissue lysate. To explore the NFkB pathway more thoroughly, we performed an NFkB protein array. Importantly, the NFkB array showed decreased expression of NFkBp65 in the calpain-inhibited ischemic myocardial tissue compared with the control. The calpain-inhibited groups also expressed decreased expression of proto-oncogene c-Rel, a member of the NFkB family of transcription factors, which has an important role in activation of B cells. Western blot data were normalized to GAPDH for each protein tested. Results are reported as fold change values compared with the high cholesterol diet (CON) group +/À SEM. Western blot data were analyzed using Kruskal-Wallis ANOVA and Dunn post hoc comparisons. All data were analyzed using GraphPad Prism 5.0 Software (GraphPad Software Inc).
The array also showed decreased expression of several cell surface receptors known to promote the NFkB pathway in the calpain-inhibited ischemic myocardial tissue compared with the control group. These receptors include TNFR1, TNFR 2, TRAIL R2. Sharpin is ubiquitously expressed in various cells and tissues and is thought to play a role in inflammatory signaling by aiding in the activation of NFkB. 21 The NFkB array identified decreased expression of Sharpin in the calpain inhibited group compared to the control.
Finally, the NFkB protein array also identified decreased expression of JNK1/2 and JNK2 in the calpain inhibited group compared with the control. JNK proteins are stress-activated proteins that can translocate to the nucleus and function as transcription factors. It is thought that JNK genes are controlled by inflammatory signals, including increased reactive oxygen species. Therefore, decreased expression of JKN1/2 and 2 may indicate decreased inflammation in the ischemic myocardial tissue of the calpain-inhibited groups compared with the control. Together, these data support the hypothesis that calpain inhibition has a beneficial effect on inflammatory signaling in ischemic myocardial tissue in the setting of metabolic syndrome (Fig 6) .
Our Western blot data showed that calpain inhibition leads to an increased expression of ICAM and PKC-a in the ischemic tissue. CD54/ICAM is a cell surface glycoprotein, which is typically expressed on endothelial cells and cells of the immune system.
The increased expression of ICAM could possibly be due to the increased presence of endothelial cells, which we have previously shown to be increased in the ischemic tissue of the calpain-inhibited groups compared with the control. 5 PKCa is stimulated through a variety of different pathways in the cell and its increased expression in the calpaininhibited groups may have been caused by other pathways activated under stress.
In the nonischemic myocardial tissue, the only change in expression level we saw was a decrease in VCAM in the calpain-inhibited groups compared with the control. VCAM is a transmembrane glycoprotein located on the endothelial cell. One explanation for the lack of effect of calpain inhibition in the nonischemic tissue is that ischemia is thought to lead to the overactivation of calpain activity and subsequent pathologic angiogenesis. Moderate calpain inhibition of this overactivation leads to improved neovessel formation and integration. A complete knockout of calpain, however, prohibits any neovessel integration and lumen formation. 22, 23 This is consistent with the results of our study, which found that calpain inhibition in the ischemic territories, where calpain is overactivated, produces a beneficial effect on inflammatory signal expression.
Finally, we used immunohistochemistry to evaluate the presence of macrophages in the ischemic myocardial tissue of our pigs. We found that in the ischemic tissue, there were increased macrophage counts in the control group compared with the HCI and LCI groups. Interestingly, in the high-cholesterol control group, the large number of macrophages were seen surrounding the blood vessels.
Our NFkB protein array showed that calpain inhibition was associated with decreased expression of IRF 5. The interferon regulator factor family serves as a molecular switch that controls whether macrophages will promote or inhibit inflammation. Macrophages have been associated with ischemia induced atherosclerosis. 24 We previously reported that calpain inhibition is associated with increased blood flow and decreased oxidative stress and cell death. Therefore, this decreased expression of macrophages in the ischemic myocardial tissue could contribute to the beneficial effects seen on blood flow associated with calpain inhibition.
Limitations. This study does not identify the optimal dose of calpain inhibition required to have a beneficial effect in the ischemic tissue and nonischemic tissue. Future dose-response studies will be required. In addition, NFkB is a transcription factor, and therefore it would be interesting to use quantitative real time-polymerase chain reaction to evaluate mRNA expression of NFkB target genes. These data are currently being collected. Due to the high experimental costs of this study design, we have not yet performed sham operations on normal-diet pigs. The nonischemic myocardial tissue is used as a baseline for all proteins of interest.
CONCLUSION
In conclusion, in the setting of metabolic syndrome and chronic myocardial ischemia, calpain inhibition modulates inflammatory protein expression in the ischemic myocardial tissue in a pig model of coronary artery disease in the setting of metabolic syndrome. We found that in the setting of metabolic syndrome and chronic myocardial ischemia, inhibition of calpain has a beneficial effect on vessel wall NFkB inflammatory signaling and is associated with decreased macrophage counts in the ischemic myocardial tissue.
Interestingly, calpain inhibition appears to regulate NFkB possibly by increasing expression of IkBa and decreasing expression of important proinflammatory mediators downstream of NFkB, including TNF-a and IL-1. Future work will need to evaluate these pathways in further detail.
